Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 21

1.

Adherence to antiretroviral therapy.

Gokarn A, Narkhede MG, Pardeshi GS, Doibale MK.

J Assoc Physicians India. 2012 Dec;60:16-20.

PMID:
23781665
2.

Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.

Mukonzo JK, Okwera A, Nakasujja N, Luzze H, Sebuwufu D, Ogwal-Okeng J, Waako P, Gustafsson LL, Aklillu E.

BMC Infect Dis. 2013 Jun 4;13:261. doi: 10.1186/1471-2334-13-261.

3.

Neurocognitive function in HIV-positive children in a developing country.

Walker SY, Pierre RB, Christie CD, Chang SM.

Int J Infect Dis. 2013 Oct;17(10):e862-7. doi: 10.1016/j.ijid.2013.02.014. Epub 2013 Apr 4.

4.

Persisting inflammation and chronic immune activation but intact cognitive function in HIV-infected patients after long-term treatment with combination antiretroviral therapy.

Pedersen KK, Pedersen M, Gaardbo JC, Ronit A, Hartling HJ, Bruunsgaard H, Gerstoft J, Ullum H, Nielsen SD.

J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):272-9. doi: 10.1097/QAI.0b013e318289bced.

PMID:
23392469
5.

Impact of HIV and aging on neuropsychological function.

Wendelken LA, Valcour V.

J Neurovirol. 2012 Aug;18(4):256-63. doi: 10.1007/s13365-012-0094-1. Epub 2012 Apr 14. Review.

6.

Antiretroviral medications disrupt microglial phagocytosis of β-amyloid and increase its production by neurons: implications for HIV-associated neurocognitive disorders.

Giunta B, Ehrhart J, Obregon DF, Lam L, Le L, Jin J, Fernandez F, Tan J, Shytle RD.

Mol Brain. 2011 Jun 7;4(1):23. doi: 10.1186/1756-6606-4-23. Review.

7.

Pathogenesis of HIV in the central nervous system.

Valcour V, Sithinamsuwan P, Letendre S, Ances B.

Curr HIV/AIDS Rep. 2011 Mar;8(1):54-61. doi: 10.1007/s11904-010-0070-4. Review.

8.

Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning?

Muñoz-Moreno JA, Fumaz CR, Prats A, Ferrer MJ, Negredo E, Pérez-Alvarez N, Moltó J, Gómez G, Garolera M, Clotet B.

J Neurovirol. 2010 May;16(3):208-18. doi: 10.3109/13550281003767710.

PMID:
20450380
9.

Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study.

Lawler K, Mosepele M, Ratcliffe S, Seloilwe E, Steele K, Nthobatsang R, Steenhoff A.

J Int AIDS Soc. 2010 Apr 20;13:15. doi: 10.1186/1758-2652-13-15.

10.

Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda.

Sacktor N, Nakasujja N, Skolasky RL, Robertson K, Musisi S, Ronald A, Katabira E, Clifford DB.

Neurology. 2009 Jan 13;72(2):165-70. doi: 10.1212/01.wnl.0000339042.96109.86.

11.

[Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].

Li H, Zheng YH, Shen Z, Liu M, Liu C, He Y, Chen J, Ou QY, Huang ZL.

Zhonghua Yi Xue Za Zhi. 2007 Nov 13;87(42):2973-6. Chinese.

PMID:
18261327
12.

Oral adverse effects due to the use of Nevirapine.

Moura MD, Senna MI, Madureira DF, Fonseca LM, Mesquita RA.

J Contemp Dent Pract. 2008 Jan 1;9(1):84-90.

PMID:
18176653
13.

Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors.

Tozzi V, Balestra P, Bellagamba R, Corpolongo A, Salvatori MF, Visco-Comandini U, Vlassi C, Giulianelli M, Galgani S, Antinori A, Narciso P.

J Acquir Immune Defic Syndr. 2007 Jun 1;45(2):174-82.

PMID:
17356465
14.

Antiretroviral therapy improves cognitive impairment in HIV+ individuals in sub-Saharan Africa.

Sacktor N, Nakasujja N, Skolasky R, Robertson K, Wong M, Musisi S, Ronald A, Katabira E.

Neurology. 2006 Jul 25;67(2):311-4.

PMID:
16864825
15.

Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells.

Al-Harthi L, Voris J, Du W, Wright D, Nowicki M, Frederick T, Landay A, Kovacs A.

J Infect Dis. 2006 May 1;193(9):1202-10. Epub 2006 Mar 17.

16.

A programmable prompting device improves adherence to highly active antiretroviral therapy in HIV-infected subjects with memory impairment.

Andrade AS, McGruder HF, Wu AW, Celano SA, Skolasky RL Jr, Selnes OA, Huang IC, McArthur JC.

Clin Infect Dis. 2005 Sep 15;41(6):875-82. Epub 2005 Aug 5.

17.

Increased frequency of CD27- (naive) B cells and their phenotypic alteration in HIV type 1-infected patients.

Chong Y, Ikematsu H, Yamamoto M, Murata M, Yamaji K, Nishimura M, Nabeshima S, Kashiwagi S, Hayashi J.

AIDS Res Hum Retroviruses. 2004 Jun;20(6):621-9.

PMID:
15242538
18.

Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity.

Hinkin CH, Castellon SA, Durvasula RS, Hardy DJ, Lam MN, Mason KI, Thrasher D, Goetz MB, Stefaniak M.

Neurology. 2002 Dec 24;59(12):1944-50.

19.

Interleukin-7 receptor expression on CD8(+) T cells is reduced in HIV infection and partially restored with effective antiretroviral therapy.

MacPherson PA, Fex C, Sanchez-Dardon J, Hawley-Foss N, Angel JB.

J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):454-7.

PMID:
11744834
20.

Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment.

Tozzi V, Balestra P, Galgani S, Narciso P, Ferri F, Sebastiani G, D'Amato C, Affricano C, Pigorini F, Pau FM, De Felici A, Benedetto A.

AIDS. 1999 Oct 1;13(14):1889-97.

PMID:
10513647
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk